A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome.

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Determine the Safety and Efficacy of Orally Administered LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2012

At a glance

  • Drugs LX 1031 (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2012 Results were published in the August 2011 issue of Gastroenterology, according to a Lexicon Pharmaceuticals media release.
    • 06 May 2010 Results presented at Digestive Disease Week.
    • 06 May 2010 Positive results of this trial have been presented at Digestive Disease Week 2010, according to a Lexicon Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top